Co-circulation HIV-1 subtypes B, C, and CRF31-BC in a drug-naïve population from Southernmost Brazil: Analysis of primary resistance mutations

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1682-1688

  de Medeiros, Rúbia Marília ^a,b   Junqueira, Dennis Maletich ^a,b   Matte, Maria Cristina Cotta ^a,b   Barcellos, Nêmora Tregnago ^c,d   Chies, José Artur Bogo ^b   Matos Almeida, Sabrina Esteves ^a,e  

^a Rio Grande do Sul   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Secretary of Health of Rio Grande do Sul State   (Brazil)

^d UNIVERSIDADE DO VALE DO RIO DOS SINOS   (Brazil)

^e UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

Genotypes; HIV 1; Primary resistance mutations; Subtypes

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; BRAZIL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS;

ADULT; ANTI-HIV AGENTS; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; PHENOTYPE; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051599193     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22188     Document Type: Article

References (32)

1. Bello G, Passaes CP, Guimarães ML, Lorete RS, Matos Almeida SE, Medeiros RM, Alencastro PR, Morgado MG. 2008. Origin and evolutionary history of HIV-1 subtype C in Brazil. AIDS 22: 1993-2000.
2. Bello G, Guimarães ML, Passaes CPB, Matos Almeida SE, Veloso VG, Morgado MG. 2009. Short communication: Evidences of recent decline in the expansion rate of the HIV type 1 subtype C and CRF31-BC epidemics in southern Brazil. AIDS Res Hum Retroviruses 25: 1065-1069.
3. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme A-M, Sandstrom P, Boucher CB, van de Vijver D, Rhee S-Y, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4: e4724.
4. Brígido LFM, Nunes CC, Oliveira CM, Knoll RK, Ferreira JLP, Freitas C, Alves M, Dias C, Rodrigues R. 2007. HIV type 1 subtype C and CB Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS Res Hum Retroviruses 23: 1579-1586.
5. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sá CAM, Eyer-Silva WA, Sion FS, Passioni LFC, Menezes JA, Calazans AR, Tanuri A. 2000. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 275: 107-115.
6. Coman RM, Robbins AH, Fernandez MA, Gilliland CT, Sochet AA, Goodenow MM, McKenna R, Dunn BM. 2008. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry 47: 731-743.
7. Dilernia DA, Lourtau L, Gomez AM, Ebenrstejin J, Toibaro JJ, Bautista CT, Marone R, Carobene M, Pampuro S, Gomez-Carrillo M, Losso MH, Salomón H. 2007. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 21: 1355-1360.
8. Geretti AM. 2006. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 19: 1-7.
9. Gifford RJ, Liu TF, Rhee S-Y, Kiuchi M, Hue S, Pillay D, Shafer RW. 2009. The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25: 1197-1198.
10. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker L-G, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng J-H, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
11. Hacker MA, Bastos FI. 2007. The first ten years: Achievements and challenges of the Brazilian program of universal access to HIV / AIDS comprehensive management and care, Os primeiros dez anos: Conquistas e desafios do programa brasileiro de acesso ao manejo e cuidado integral. Cad Saúde Pública 23 (Suppl 3): 345-359.
12. Inocencio LA, Pereira AA, Sucupira MCA, Fernandez JCC, Jorge CP, Souza DF, Fink HT, Diaz RS, Becker IM, Suffert TA, Arruda MB, Macedo O, Simão MB, Tanuri A. 2009. Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc 12: 20.
13. Johnson JA, Geretti AM. 2010. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 65: 1322-1326.
14. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares Ma, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme A-M, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2: e112.
15. Kimura M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16: 111-120.
16. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789-1796.
17. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ. 2005. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 79: 7121-7134.
18. Osmanov S, Pattou C, Walker N, Schwardländer B, Esparza J. 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29: 184-190.
19. Passaes CPB, Bello G, Lorete RS, Matos Almeida SE, Junqueira DM, Veloso VG, Morgado MG, Guimarães ML. 2009. Genetic characterization of HIV-1 BC recombinants and evolutionary history of the CRF31-BC in Southern Brazil. Infect Genet Evol 9: 474-482.
20. Robbins AH, Coman RM, Bracho-Sanchez E, Fernandez M, Gilliland CT, Li M, Agbandje-McKenna M, Wlodawer A, Dunn BM, McKenna R. 2010. Structure of the unbound form of HIV-1 subtype A protease: Comparison with unbound forms of proteases from other HIV subtypes. Acta Crystallogr 66: 233-242.
21. Robertson DL, Anderson JP, Bradac J, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B. 2000. HIV-1 nomenclature proposal. Science 288: 55-56.
22. Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JLP, Castro SM, Stella IM, Brigido LFM. 2006. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116: 201-207.
23. Santos AF, Soares M. 2010. HIV Genetic diversity and drug resistance. Viruses 2: 503-531.
24. Santos AF, Sousa TM, Soares EA, Sanabani S, Martinez AM, Sprinz E, Silveira J, Sabino EC, Tanuri A, Soares M. 2006. Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil. AIDS 20: 2011-2019.
25. Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21: 215-223.
26. Shekelle P, Maglione M, Geotz MB, Wagner G, Wang Z, Hilton L, Carter J, Chen S, Tringle C, Mojica W, Newberry S. 2007. Antiretroviral (ARV) drug resistance in the developing world. AHRQ Publication 07-E014.
27. Soares M, Brindeiro RM, Tanuri A. 2004. Primary HIV-1 drug resistance in Brazil. AIDS 18: S9-S13.
28. Soares EJM, Santos AF, Sousa TM, Sprinz E, Martinez AMB, Silveira J, Tanuri A, Soares M. 2007. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2: e730.
29. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
30. Taylor BS, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. N Engl J Med 358: 1590-1602.
31. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL-X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
32. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, Delaporte E. 2000. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919-3925.